GlassScriptPhysician profile
Tung T Tran
NPI 1396958484
$170,786.32
in general payments reported to CMS, 2019-2025
30 companies · $24K in 2025
The $24K reported for 2025 was more than what 95% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58K · 2020: $10K · 2021: $27K · 2022: $22K · 2023: $23K · 2024: $6,376 · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $49K · Food and Beverage: $4,101 · Travel and Lodging: $770.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $48,587.50 |
| Food and Beverage | $4,101.11 |
| Travel and Lodging | $770.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $102,335.77 | 2019-2025 | Linzess, Rinvoq, Skyrizi |
| Allergan, INC. | $61,519.39 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $3,200.84 | 2019-2023 | Linzess |
| Boston Scientific Corporation | $654.36 | 2019-2025 | Axonics |
| Takeda Pharmaceuticals U.S.A., INC. | $570.99 | 2020-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $343.63 | 2020-2025 | Xifaxan, Relistor, Plenvu |
| Ardelyx, INC. | $306.41 | 2022-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $217.07 | 2022-2025 | Dupixent |
| Genzyme Corporation | $198.75 | 2022-2025 | |
| Medtronic, INC. | $172.82 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $144.24 | 2024-2025 | Vowst |
| Phathom Pharmaceuticals, INC. | $130.87 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $127.19 | 2019 | |
| Gilead Sciences, INC. | $126.97 | 2025 | Vemlidy |
| Braintree Laboratories, INC. | $109.14 | 2023-2025 | Suflave, Sutab |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $98.13 | 2025 | Rezdiffra |
| Axonics, INC. | $94.10 | 2022-2024 | Axonics |
| Janssen Biotech, INC. | $72.26 | 2022-2024 | Simponi Aria, Simponi, Stelara |
| Shionogi INC | $58.73 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $56.36 | 2023 | |
| Intercept Pharmaceuticals, INC. | $38.36 | 2019-2020 | |
| Novo Nordisk INC | $35.19 | 2025 | Wegovy |
| Lilly USA, LLC | $33.33 | 2025 | Omvoh |
| Revance Therapeutics, INC. | $27.50 | 2025 | Daxxify |
| Shire North American Group INC | $27.20 | 2019 | |
| Celltrion USA INC. | $23.63 | 2025 | Vegzelma |
| Ipsen Biopharmaceuticals, INC | $22.64 | 2024 | Iqirvo |
| Azurity Pharmaceuticals, INC. | $17.84 | 2025 | Sutab |
| Intra-Sana Laboratories | $13.88 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Vivus LLC | $8.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tung Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.